Aldeyra Therapeutics Inc. (NASDAQ: ALDX)
$3.97
+0.1050 ( +2.72% ) 218.7K
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Market Data
Open
$3.97
Previous close
$3.86
Volume
218.7K
Market cap
$235.28M
Day range
$3.75 - $3.97
52 week range
$1.42 - $8.38
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 21 | Jun 20, 2024 |
8-k | 8K-related | 14 | Jun 13, 2024 |
8-k | 8K-related | 13 | Jun 07, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
10-q | Quarterly Reports | 69 | May 02, 2024 |